2819 Waldman, Scott - Thomas Jefferson University - Thomas Jefferson University

Scott A.. Waldman, MD, PhD

Contact Dr. Waldman

132 South 10th Street
Suite 1170
Philadelphia, PA 19107

(215) 955-6086
(215) fax

Most Recent Peer-reviewed Publications

  1. Bioinnovation Enterprise: An Engine Driving Breakthrough Therapies
  2. CD19-targeted nanodelivery of doxorubicin enhances therapeutic efficacy in B-cell acute lymphoblastic leukemia
  3. Companion diagnostics at the intersection of personalized medicine and healthcare delivery
  4. Clinical pharmacology & therapeutics: The next five years
  5. A novel CDX2 isoform regulates alternative splicing
  6. Tumor radiation therapy creates therapeutic vaccine responses to the colorectal cancer antigen GUCY2C
  7. Managing the innovation supply chain to maximize personalized medicine
  8. Antiobesity pharmacotherapy: New drugs and emerging targets
  9. GUCY2C lysosomotropic endocytosis delivers immunotoxin therapy to metastatic colorectal cancer
  10. Policies to aid the adoption of personalized medicine
  11. Selective antigen-specific CD4+ T-cell, but not CD8+ T- or B-cell, tolerance corrupts cancer immunotherapy
  12. Molecular insights provide the critical path to disease mitigation
  13. The paracrine hormone for the GUCY2C tumor suppressor, guanylin, is universally lost in colorectal cancer
  14. Erratum: Cardiopoietic stem cell therapy in heart failure: The C-CURE (Cardiopoietic stem Cell therapy in heart failURE) Multicenter randomized trial with lineage-specified biologics (Journal of the American College of Cardiology (2013) 61 (2329-2338))
  15. Genetics and genomics for the prevention and treatment of cardiovascular disease: Update a scientific statement from the american heart association
  16. Reply: The C-CURE randomized clinical trial (Cardiopoietic stem Cell therapy in heart failURE)
  17. Intestinal GUCY2C prevents TGF-β secretion coordinating desmoplasia and hyperproliferation in colorectal cancer
  18. Advances in cancer immunotherapy
  19. Colorectal cancer immunotherapy
  20. Translating colorectal cancer prevention through the guanylyl cyclase C signaling axis